Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours

Endocrine

Volumn 40, Issue 2, 2011, Pages 181-186

  Yim, Kein Leong ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Bevacizumab; Carcinoid; Everolimus; Neuroendocrine; Pancreatic; Sunitinib

Indexed keywords

BEVACIZUMAB; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; OCTREOTIDE; PEGINTERFERON ALPHA2B; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ANEMIA; ANTIANGIOGENIC THERAPY; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CARCINOID; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; GRANULOCYTOPENIA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROENDOCRINE TUMOR; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; STOMATITIS; TREATMENT OUTCOME;

EID: 84855192661     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-011-9513-y     Document Type: Review

References (26)

1. S. La Rosa, S. Uccella, G. Finzi, L. Albarello, F. Sessa, C. Capella, Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features. Hum. Pathol. 34, 2-18 (2003)
2. B. Terris, J.Y. Scoazec, L. Rubbia, L. Bregeaud, M.S. Pepper, P. Ruszniewski, J. Belghiti, J. Flejou, C. Degott, Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology 32, 133-138 (1998) (Pubitemid 28126179)
3. J. Zhang, Z. Jia, Q. Li, L. Wang, A. Rashid, Z. Zhu, D.B. Evans, J.N. Vauthey, K. Xie, J.C. Yao, Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with lowgrade neuroendocrine tumors. Cancer 109, 1478-1486 (2007) (Pubitemid 46595681)
4. S.R. Silva, K.A. Bowen, P.G. Rychahou, L.N. Jackson, H.L. Weiss, E.Y. Lee, C.M. Townsend Jr, B.M. Evers, VEGFR-2 expression in carcinoid cancer cells and its role in tumor growth and metastasis. Int. J. Cancer 128, 1045-1056 (2011)
5. T. Shah, D. Hochhauser, R. Frow, A. Quaglia, A.P. Dhillon, Caplin, M.E.: Epidermal growth factor receptor expression and activation in neuroendocrine tumours. J. Neuroendocrinol. 18, 355-360 (2006)
6. J.C. Yao, A. Phan, P.M. Hoff, H.X. Chen, C. Charnsangavej, S.C. Yeung, K. Hess, C. Ng, J.L. Abbruzzese, J.A. Ajani, Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J. Clin. Oncol. 26, 1316-1323 (2008)
7. M.H. Kulke, H.J. Lenz, N.J. Meropol, J. Posey, D.P. Ryan, J. Picus, E. Bergsland, K. Stuart, L. Tye, X. Huang, Activity of sunitinib in patients with advanced neuroendocrine tumors. J. Clin. Oncol. 26, 3403-3410 (2008)
8. E. Raymond, L. Dahan, J.L. Raoul, Y.J. Bang, I. Borbath, C. Lombard-Bohas, J. Valle, P. Metrakos, D. Smith, A. Vinik, Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. NEJM 364, 501-513 (2011)
9. T.J. Hobday, J. Rubin, K. Holen, J. Picus, R. Donehower, R. Marschke, W. Maples, R. Lloyd, M. Mahoney, C. Erlichman, MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): A phase II Consortium (P2C) study. J. Clin. Oncol. 25, abstract 4504 (2007)
10. I. Duran, J. Kortmansky, D. Singh, H. Hirte, W. Kocha, G. Goss, L. Le, A. Oza, T. Nicklee, J. Ho, A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br. J. Cancer 95, 1148-1154 (2006) (Pubitemid 44660065)
11. J.C. Yao, A.T. Phan, D.Z. Chang, R.A. Wolff, K. Hess, S. Gupta, C. Jacobs, J.E. Mares, A.N. Landgraf, A. Rashid, Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: Results of a phase II study. J. Clin. Oncol. 26, 4311-4318 (2008)
12. J.C. Yao, C. Lombard-Bohas, E. Baudin, L.K. Kvols, P. Rougier, P. Ruszniewski, S. Hoosen, J. St.Peter, T. Haas, D. Lebwohl, Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: A phase II trial. J. Clin. Oncol. 28, 69-76 (2010)
13. J.C. Yao, M.H. Shah, T. Ito, C.L. Bohas, E.M. Wolin, E. Van Cutsem, T.J. Hobday, T. Okusaka, J. Capdevila, E.G. de Vries, Everolimus for advanced pancreatic neuroendocrine tumors. NEJM 354, 514-523 (2011)
14. M.H. Shah, T. Ito, C. Lombard-Bohas, E.M. Wolin, E. Van Cutsem, C. Sachs, R.E. Winkler, J. Lincy, T.J. Hobday, J.C. Yao, Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Updated results of a randomized, double-blind, placebo-controlled, multicenter phase III trial (RADIANT-3). J. Clin. Oncol. 29, 158 (2011)
15. J.C. Yao, J.D. Hainsworth, E. Baudin, M. Peeters, D. Hoersch, L.B. Anthony, J. Klimovsky, K. Grouss, V. Jehl, M. Pavel, Everolimus plus octreotide LAR (E ? O) versus placebo plus octreotide LAR (P ? O) in patients with advanced neuroendocrine tumors (NET): Updated results of a randomized, doubleblind, placebo-controlled, multicenter phase III trial (RADIANT-2). J Clin Oncol 29, 159 (2011)
16. J.C. Yao, A.T. Phan, D. Fogleman, C.S. Ng, C.B. Jacobs, C.D. Dagohoy, C. Leary, K.R. Hess, Randomized run-in study of bevacizumab (B) and everolimus (E) in low- to intermediategrade neuroendocrine tumors (LGNETs) using perfusion CT as functional biomarker. J. Clin. Oncol. 28, abstract 4002 (2010)
17. G. Vitale, W.W. de Herder, P.M. van Koetsveld, M. Waaijers, W. Schoordjk, E. Croze, A. Colao, S.W.J. Lamberts, L.J. Hofland, IFN-b is a highly potent inhibitor of gastroenteropancreatic neuroendocrine tumor cell growth in vitro. Cancer Res. 66(1), 554-562 (2006) (Pubitemid 43166064)
18. G. Vitale, P.M. van Koetsveld, W.W. de Herder, K. van der Wansem, J.A. Janssen, A. Colao, G. Lombardi, S.W. Lamberts, L.J. Hofland, Effects of type I interferons on IGF-mediated autocrine/paracrine growth of human neuroendocrine tumor cells. Am. J. Physiol. Endocrinol. Metab. 296(3), E559-E566 (2009)
19. A.W. Tolcher, M.L. Rothenberg, J. Rodon, D. Delbeke, A. Patnaik, L. Nguyen, F. Young, Y. Hwang, C. Haqq, I. Puzanov, Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J. Clin. Oncol. 27, 5800-5807 (2009)
20. D.L. Reidy, E. Hollywood, M. Segal, L. Saltz, A phase II clinical trial of MK-0646, an insulin-like growth factor-1 receptor inhibitor (IGF-1R), in patients with metastatic well-differentiated neuroendocrine tumors (NETs). ASCO Meeting Abstracts, vol. 28 (2010), p. 4163
21. L. Kvols, B. Wiedenmann, K. Oberg, J. Glusman, T. O'Dorisio, W. de Herder, B. Gao, R. Arnold, L. Anthony, SOM230 Carcinoid Study Group, Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: Results of a phase II study. ASCO Gastrointestinal Cancers Symposium, Abstract 171, 2006
22. K.E. Oberg, J.C. Reubi, D.J. Kwekkeboom, E.P. Krenning, Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology 139(3), 742-753, 753.e1 (2010)
23. M. Caraglia, M. Marra, P. Tagliaferri, S.W. Lamberts, S. Zappavigna, G. Misso, F. Cavagnini, G. Facchini, A. Abbruzzese, L.J. Hofland, G. Vitale, Emerging strategies to strengthen the anti-tumour activity of type I interferons: overcoming survival pathways. Curr. Cancer Drug Targets 9(5), 690-704 (2009)
24. E. Allen, I.B. Walters, D. Hanahan, Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line againstmouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition. Clin. Cancer Res. 17(16), 5299-5310 (2011)
25. E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228-247 (2009)
26. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, New guidelines to evaluate the response to treatment in solid tumors (RECIST Guidelines). J. Natl. Cancer Inst. 92, 205-216 (2000) (Pubitemid 30099779)